Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of marstacimab prophylaxis in severe hemophilia A and B
jRCT2041220046Recruiting
- Sponsor
- Pfizer
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Open-label trial of marstacimab in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Pfizer. Primary endpoints: Number of subjects reporting Adverse Events, Number of subjects reporting Serious Adverse Events and 8 more. Started Sep 2022; status: recruiting.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on jRCT2041220046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220046.